# A Study to Evaluate Pharmacokinetics (PK) and Safety of Subcutaneous (SC) Ublituximab Administered at Various Injection Sites and Relative Bioavailability Via Autoinjector (AI) Versus Syringe Subcutaneously in Participants With Multiple Sclerosis (MS)

> clinical trial · VERIFIED · 2026-08-21

Status: RECRUITING · Sponsor: TG Therapeutics, Inc. · Condition: Multiple Sclerosis

- Company: TG Therapeutics, Inc.
- Sector: biotech
- Primary source: https://clinicaltrials.gov/study/NCT07503873

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.